Form D · Pharmaceuticals
CNS Pharmaceuticals, Inc.
Houston, TX · CIK 0001729427
Offering snapshot reported May 19, 2026 · SEC filing
- Reported sold
- $22.5M Offering amount: $22.5M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 4, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 19, 2026 | Initial | $22,525,000 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.58M
- Finders' fees
- $0
- Form D file number
- 021-584551
Cash payment equal to 7.0% of gross proceeds, plus up to $75,000 reimbursement for fees and expenses and $15,000 for non-accountable expenses.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| A.G.P./Alliance Global Partners | 000008361 |
Source: Form D, filed May 19, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Faith Charles | Director |
| Bettina Cockroft | Director |
| Michal Fisher | Director |
| Jeffry Keyes | Director |
| Rami Levin | Director, Executive |
| Amy Mahery | Director |
| Steve O'loughlin | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2100 West Loop South Suite 900
Houston, TX, 77027
Houston, TX, 77027